Nivolumab provides improved effectiveness and safety compared with docetaxel as a second‐line treatment for advanced non‐small cell lung cancer: A systematic review and meta‐analysis

BACKGROUND: As an inhibitor of programmed death‐1 (PD‐1) protein, nivolumab has been shown to be effective in various cancers. We thus conducted this meta‐analysis to compare the relative efficacy of nivolumab vs docetaxel‐based chemotherapy as a second‐line treatment for previously treated advanced...

Descripción completa

Detalles Bibliográficos
Autores principales: Xu, Zheng, Yi, Fengming, Yu, Dongliang, Xu, Jianjun, Wei, Yiping, Zhang, Wenxiong
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2019
Materias:
Clinical Cancer Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6382729/
https://www.ncbi.nlm.nih.gov/pubmed/30628185
http://dx.doi.org/10.1002/cam4.1966

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6382729/
https://www.ncbi.nlm.nih.gov/pubmed/30628185
http://dx.doi.org/10.1002/cam4.1966

Ejemplares similares